Cargando…

Sustained Intraocular Pressure Elevation After Intravitreal Injection of Bevacizumab and Ranibizumab Associated with Trabeculitis

Anti-vascular endothelial growth factor agents are frequently used to treat a variety of ocular neovascular diseases. While agents like bevacizumab and ranibizumab appear to be safe and effective, there have been reports of severe intraocular inflammation as well as sustained elevation of intraocula...

Descripción completa

Detalles Bibliográficos
Autores principales: Sniegowski, Matthew, Mandava, Naresh, Kahook, Malik Y
Formato: Texto
Lenguaje:English
Publicado: Bentham Open 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2944993/
https://www.ncbi.nlm.nih.gov/pubmed/20871754
http://dx.doi.org/10.2174/1874364101004010028
_version_ 1782187155907411968
author Sniegowski, Matthew
Mandava, Naresh
Kahook, Malik Y
author_facet Sniegowski, Matthew
Mandava, Naresh
Kahook, Malik Y
author_sort Sniegowski, Matthew
collection PubMed
description Anti-vascular endothelial growth factor agents are frequently used to treat a variety of ocular neovascular diseases. While agents like bevacizumab and ranibizumab appear to be safe and effective, there have been reports of severe intraocular inflammation as well as sustained elevation of intraocular pressure (IOP) after single or multiple intravitreal injections of these protein-based therapeutics. The true mechanism leading to inflammation and/or sustained spikes in IOP remains unknown. We report a patient with sustained IOP elevation and kerato-precipitates on the trabecular meshwork after multiple injections of both bevacizumab and ranibizumab. We propose that monomer antibodies, aggregated proteins, or other high molecular weight molecules might lead to inflammation in the trabecular meshwork and subsequent elevation in IOP.
format Text
id pubmed-2944993
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Bentham Open
record_format MEDLINE/PubMed
spelling pubmed-29449932010-09-24 Sustained Intraocular Pressure Elevation After Intravitreal Injection of Bevacizumab and Ranibizumab Associated with Trabeculitis Sniegowski, Matthew Mandava, Naresh Kahook, Malik Y Open Ophthalmol J Article Anti-vascular endothelial growth factor agents are frequently used to treat a variety of ocular neovascular diseases. While agents like bevacizumab and ranibizumab appear to be safe and effective, there have been reports of severe intraocular inflammation as well as sustained elevation of intraocular pressure (IOP) after single or multiple intravitreal injections of these protein-based therapeutics. The true mechanism leading to inflammation and/or sustained spikes in IOP remains unknown. We report a patient with sustained IOP elevation and kerato-precipitates on the trabecular meshwork after multiple injections of both bevacizumab and ranibizumab. We propose that monomer antibodies, aggregated proteins, or other high molecular weight molecules might lead to inflammation in the trabecular meshwork and subsequent elevation in IOP. Bentham Open 2010-06-22 /pmc/articles/PMC2944993/ /pubmed/20871754 http://dx.doi.org/10.2174/1874364101004010028 Text en © Sniegowski et al.; Licensee Bentham Open. http://creativecommons.org/licenses/by-nc/3.0/ This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
spellingShingle Article
Sniegowski, Matthew
Mandava, Naresh
Kahook, Malik Y
Sustained Intraocular Pressure Elevation After Intravitreal Injection of Bevacizumab and Ranibizumab Associated with Trabeculitis
title Sustained Intraocular Pressure Elevation After Intravitreal Injection of Bevacizumab and Ranibizumab Associated with Trabeculitis
title_full Sustained Intraocular Pressure Elevation After Intravitreal Injection of Bevacizumab and Ranibizumab Associated with Trabeculitis
title_fullStr Sustained Intraocular Pressure Elevation After Intravitreal Injection of Bevacizumab and Ranibizumab Associated with Trabeculitis
title_full_unstemmed Sustained Intraocular Pressure Elevation After Intravitreal Injection of Bevacizumab and Ranibizumab Associated with Trabeculitis
title_short Sustained Intraocular Pressure Elevation After Intravitreal Injection of Bevacizumab and Ranibizumab Associated with Trabeculitis
title_sort sustained intraocular pressure elevation after intravitreal injection of bevacizumab and ranibizumab associated with trabeculitis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2944993/
https://www.ncbi.nlm.nih.gov/pubmed/20871754
http://dx.doi.org/10.2174/1874364101004010028
work_keys_str_mv AT sniegowskimatthew sustainedintraocularpressureelevationafterintravitrealinjectionofbevacizumabandranibizumabassociatedwithtrabeculitis
AT mandavanaresh sustainedintraocularpressureelevationafterintravitrealinjectionofbevacizumabandranibizumabassociatedwithtrabeculitis
AT kahookmaliky sustainedintraocularpressureelevationafterintravitrealinjectionofbevacizumabandranibizumabassociatedwithtrabeculitis